Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes

Nature Reviews Drug Discovery

Volumn 3, Issue 3, 2004, Pages 215-225

  Matthews, Tom ^a   Salgo, Miklos ^b   Greenberg, Michael ^a   Chung, Jain ^b   DeMasi, Ralph ^a   Bolognesi, Dani ^a  

^a Trimeris Inc   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ANALGESIC AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DAPSONE; DEBRISOQUINE; ENFUVIRTIDE; GLYCOPROTEIN; MEPHENYTOIN; OKT 4; PRO 140; PROTEINASE INHIBITOR; RANTES; RECEPTOR BLOCKING AGENT; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SCH C; T 1249; TNX 355; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; ANOREXIA; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ERYTHEMA; FATIGUE; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LYMPHADENOPATHY; MALE; MONOTHERAPY; MOUSE; NAUSEA; NONHUMAN; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINUSITIS; SKIN CYST; SKIN MANIFESTATION; SKIN NODULE; T LYMPHOCYTE; TUBERCULOSIS; VIRUS LOAD; VIRUS STRAIN; VOMITING; WEIGHT REDUCTION;

EID: 1642391068     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1331     Document Type: Review

References (88)

1. King, J. T. Jr et al. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med. Decis. Making 23, 9-20 (2003).
2. Kitchen, C. M. et al. Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. Clin. Infect. Dis. 33, 466-472 (2001).
3. Valenti, W. M. HAART is cost-effective and improves outcomes. AIDS Read. 11, 260-262 (2001).
4. Richman, D. D. et al. The prevalence of antiretroviral drug resistance in the US. 41st Intersci. Conf. Antimicrob. Agents Chemother. A LB-17 (2001).
5. Little, S. E. et al. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347, 385-394 (2002).
6. Hammer, S. M. HIV drug resistance: Implications for management. Top. HIV Med. 10, 10-15 (2002).
7. Kuritzkes, D. R. et al. Current management challenges in HIV: antiretroviral resistance. AIDS Pead. 13, 133-142 (2003).
8. Montaner, J. S. & Mellors, J. W. Antiretroviral therapy for previously treated patients. N. Engl. J. Med. 345, 452-455 (2001).
9. Richman, D. D. HIV chemotherapy. Nature 410, 995-1001 (2001).
10. Eckert, D. M. & Kim, P. S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777-810 (2001).
11. LaBranche, C. C. et al. HIV fusion and its inhibition. Antiviral Res. 60, 95-115 (2001).
12. Einfeld, D. & Hunter, E. Oligomeric structure of a prototype retrovirus glycoprotein. Proc. Natl Acad. Sci. USA 85, 8688-8692 (1988).
13. Pinter, A. et al. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J. Virol. 63, 2674-2679 (1989).
14. Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884-1888 (1998).
15. Munoz-Barroso, I. et al. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J. Cell. Biol. 140, 315-323 (1998).
16. Matthews, T. J. et al. Structural rearrangements in the transmembrane glycoprotein after receptor binding. Immunol. Rev. 140, 93-104 (1994).
17. Wild, C. et al. A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition. Proc. Natl Acad. Sci. USA 89, 10537-10541 (1992).
18. Wild, C. et al. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl Acad. Sci. USA 91, 12676-12680 (1994).
19. Wild, C., Greenwell, T. & Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 9, 1051-1053 (1993).
20. Wild, C. T. et al. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl Acad. Sci. USA 91, 9770-9774 (1994).
21. Chen, C. H. et al. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: Implication for viral fusion. J. Virol. 69, 3771-3777 (1995).
22. Kliger, Y. et al. Mode of action of an antiviral peptide from HIV-1. J. Biol. Chem. 276, 1391-1397 (2001).
23. Kilby, J. M. et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4, 1302-1307 (1998).
24. Kilby, J. M. et al. The safety plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retroviruses 18, 685-693 (2002).
25. Sista, P. et al. Subgroup analysis of baseline (BL) susceptibility and early virological response to enfuvirtide in the combined TORO studies. Antivir. Ther. 8, S60 (2003).
26. Lalezari, J. P. et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 17, 691-698 (2003).
27. Lalezari, J. P. et al. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir. Ther. 8, 279-287 (2003).
28. Wheeler, D. A. et al. Safety, tolerability and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients. J. Clin. Virol. (in the press).
29. Drobnes, C. et al. Tolerability of enfuvirtide (T-20) during chronic therapy in Phase II trials. 42nd Intersci. Conf. Antimicrob. Agents Chemother. A H-171 (2002).
30. Lalezari, J. P. et al. Influence of subcutaneous injection site on the steady state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J. Clin. Virol. 28, 217-222 (2003).
31. Zhang, X. et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition. Clin. Pharmacol. Ther. 72, 10-19 (2002).
32. Zhang, X. et al. Assessment of metabolic inhibition potential of enfuvirtide using a 5-drug cocktail in HIV-1 infected patients. Am. Soc. Clin. Pharmacol. Ther. A PIII-73 (2003).
33. Boyd, M. et al. Enfuvirtide - investigations on the drug interaction potential in HIV-infected patients. 10th Conf. Retrovir. Opportunistic Infect. A541 (2003).
34. Zhang, X. et al. Enfuvirtide pharmacokinetic-pharmacodynamic (PK-PD) relationship. 9th Eur. AIDS Conf. A4.1/4 (2003).
35. Lalezari, J. P. et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348, 2175-2185 (2003).
36. Lazzarin, A. et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348, 2186-2195 (2003).
37. Delfraissy, J. F. et al. Summary of pooled efficacy and safety analyses of enfuvirtide (ENF) treatment for 24 weeks in TORO 1 and TORO 2 Phase III trials in highly antiretroviral (ARV) treatment-experienced patients. 10th Conf. Retrovir. Opportunistic Infect. A568 (2003).
38. Katlama, C. et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. 2nd Int. AIDS Soc. Conf. HIV Pathog. Treat. A LB2 (2003).
39. Trottier, B. et al. Durability of response of enfuvirtide through 48 weeks in the TORO trials. 43rd Intersci. Conf. Antimicrob. Agents Chemother. A H-835 (2003).
40. Walmsley, S. et al. Efficacy of enfuvirtide in subgroups of patients through 48 weeks of therapy in the TORO trials. 9th Eur. AIDS Conf. A7.3/15 (2003).
41. Lalezari, J. et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone: Week 24 response among categories of treatment experience and baseline (BL) HIV antiretroviral (ARV) resistance. 42nd Intersci. Conf. Antimicrob. Agents Chemother. A3232 (2002).
42. Lange, J. et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone: Week 24 response among categories of treatment experience and baseline (BL) demographics, treatment experience and HIV anti-retroviral (ARV) resistance. 6th Int. Congress Drug Ther. HIV Infect. A PL14.3 (2002).
43. Montaner, J. et al. Analysis of virological response to enfuvirtide in TORO: Implications for patient management. 2nd Intern AIDS Soc. Conf. HIV Pathog. Treat. A116 (2003).
44. Battegay, M. et al. Analysis of virological failure through 24 weeks of treatment in the TORO pivotal studies. 2nd Int. AIDS Soc. Conf. HIV Pathog. Treat. A574 (2003).
45. Rimsky L. T., Shugars, D. C. & Matthews, T. J. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72, 986-993 (1998).
46. Chan, D. C. et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (1997).
47. Weissenhorn, W. et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430 (1997).
48. Wei, X. et al. HIV-1 selection in response to inhibition of virus fusion and entry. 6th Conf. Retrovir. Opportunistic Infect. A611 (1999).
49. Mink, M. et al. Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility of T-20 (enfuvirtide) in vitro: analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3. Antivir. Ther. 7, S24 (2002).
50. Mink, M. A. et al. Correlation of gp41 binding and antiviral potencies of the T-20 fusion inhibitor using clinical trial isolate-derived sequences. 8th Conf. Retrovir. Opportunistic Infect. A474 (2001).
51. Sista, P. et al. Characterization of baseline and treatment-emergent resistance to T-20 (enfuvirtide) observed in Phase II trials: Substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates. Antivir. Ther. 7, S16 (2002).
52. Lu, J. & Kuritzkes, D. R. Impaired fitness of human immunodeficiency virus type 1 site-directed mutants resistant to T-20. 5th Int. Workshop HIV Drug Resist. Treat. Strateg. A23 (2001).
53. Lu, J. et al. Fitness of HIV-1 clinical isolates resistant to T-20 (enfuvirtide). Antivir. Ther. 7, S74 (2002).
54. Derdeyn, C. A. et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves district regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 75, 8605-8614 (2001).
55. Derdeyn, C. A. et al. Sensitivity of HIV-1 to the fusion inhibitors T-20 and T-649 is modulated by coreceptor specificity and involves distinct regions of gp41. 8th Conf. Retrovir. Opportunistic Infect. A475 (2001).
56. Reynes, J. et al. SCH C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects. 9th Conf. Retrovir. Opportunistic Infect. A1 (2002).
57. Greenberg, M. L. et al. Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage. 8th Conf. Retrovir. Opportunistic Infect. A473 (2001).
58. Whitcomb, J. M. et al. Analysis of baseline enfuvirtide (T20) susceptibility and co-receptor tropism in two Phase III study populations. 10th Conf. Retrovir. Opportunistic Infect. A557 (2003).
59. Greenberg, M. et al. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 through 24 weeks. 10th Conf. Retrovir. Opportunistic Infect. A141 (2003).
60. Eron, J. et al. Safety of enfuvirtide (ENF) through 48 weeks of therapy in the TORO trials. 43rd Intersci. Conf. Antimicrob. Agents Chemother. A H-836 (2003).
61. Ball, R. A. & Kinchelow, T. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J. Am. Acad. Dermatol. 49, 826-831 (2003).
62. Walmsley, S. et al. Enfuvirtide (T-20) cross-reactive gp41 antibody has no effect on the efficacy or safety of enfuvirtide in the TORO 1 and TORO 2 Phase III trials. J. Infect. Dis. 188, 1827-1833 (2003).
63. Cohen, C. et al. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clin. Trials 4, 347-357 (2003).
64. Cohen, C. et al. Patient acceptance with self-injection of enfuvirtide (ENF) for HIV over 48 weeks of treatment. 9th Eur. AIDS Conf. A7.1/1 (2003).
65. Clumeck, N. et al. Impact of enfuvirtide on health-related quality of life at 48 weeks. 9th Eur. AIDS Conf. A 7.3/19 (2003).
66. Kilby, J. M. & Eron, J. J. Novel therapies based on mechanisms of HIV-1 cell entry N. Engl. J. Med. 348, 2228-2238 (2003).
67. Lin, P. F. et al. Identification and characterization of a novel inhibitor of HIV-1 entry - II: Mechanism of action. 9th Conf. Retrovir. Opportunistic Infect. A10 (2002).
68. Kuritzkes, D. R. et al. Safety and preliminary anti-HIV activity of an anti-CD4 mAb (TNX-355; formerly Hu5A8) in HIV-infected patients. 10th Conf. Retrovir. Opportunistic Infect. A13 (2003).
69. Franti, M. et al. PRO 542 (CD4-IgG2) has a profound impact on HIV-1 replication in the Hu-PBL-SCID mouse model. 9th Conf. Retrovir. Opportunistic Infect. A410-T (2002).
70. Jacobson, J. M. et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. 182, 326-329 (2000).
71. Nagashima, K. et al. Mechanisms of synergy between HIV-1 attachment, coreceptor and fusion inhibitors. 8th Conf. Retrovir. Opportunistic Infect. A310 (2001).
72. Olson, W. C. et al. Potent, synergistic inhibition of HIV-1 by combinations of the viral entry inhibitors PRO-542 and T-20. 40th Intersci. Conf. Antimicrob. Agents Chemother. A549 (2000).
73. Trkola, A. et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69, 6609-6617 (1995).
74. Dragic, T. et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl Acad. Sci. USA 97, 5639-5644 (2000).
75. Takashima, K. et al. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication. Antimicrob. Agents Chemother. 45, 3538-3543 (2001).
76. Tremblay, C. L. et al. In vitro synergy observed between the fusion inhibitor T-20 and a CCR5 inhibitor TAK-779. 40th Intersci. Conf. Antimicrob. Agents Chemother. A1164 (2000).
77. Tremblay, C. L. et al. TAK-220, a novel small molecular inhibitor of CCR5 has favorable anti-HIV interactions with other antiretrovirals in vitro. 10th Conf. Retrovir. Opportunistic Infect. A562 (2003).
78. Franti, M. et al. The CCR5 co-receptor inhibitor PRO 140 effectively controls established HIV-1 infections in vivo. 9th Conf. Retrovir. Opportunistic Infect. A403-T (2002).
79. Tremblay, C. L. et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. 46, 1336-1339 (2002).
80. Ketas, T. J. et al. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res. Hum. Retroviruses 19, 177-186 (2003).
81. Riley, J. et al. Genotypic and phenotypic analysis of in vitro generated HIV-1 escape isolates to the CCR5 antagonist SCH-C. 9th Conf. Retrovir. Opportunistic Infect. A397-T (2002).
82. Stoddart, C. et al. Evaluation of in vivo HIV-1 escape from SCH-C (SCH 351125). 10th Conf. Retrovir. Opportunistic Infect. A614 (2003).
83. Tremblay, C. et al. Strong in vitro synergy observed between the fusion inhibitor T-20 and a CXCR4 blocker AMD-3100. 7th Conf. Retrovir. Opportunistic Infect. A500 (2000)
84. Greenberg, M. L. et al. Enfuvirtide (T-20) and T-1249 resistance: Observations from Phase II clinical trials of enfuvirtide in combination with oral antiretrovirals (ARVs) and a Phase I/II dose-ranging monotherapy trial of T-1249. 11th Int. HIV Drug Resist. Workshop. A128 (2002).
85. Gulick, R. et al. Complete analysis of T1249-101: Safety, pharmacokinetics, and antiviral activity of T-1249, a peptide inhibitor of HIV membrane fusion. 42nd Intersci. Conf. Antimicrob. Agents Chemother. A850 (2002).
86. Miralles, G. D. et al. Baseline genotype and prior antiretroviral history do not affect virological response to T-1249. 5th Int. Workshop HIV Drug Resist. Treat. Strateg. A3 (2001).
87. Miralles, G. D. et al. Genotypic resistance to protease and reverse transcriptase inhibitors and antiretroviral history do not affect virologic response to T-1249. 41st Intersci. Conf. Antimicrob. Agents Chemother. A669 (2001).
88. De Clercq, E. Strategies in the design of antiviral drugs. Nature Rev. Drug Disc. 1, 13-25 (2002).